Clinical trial
Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease
NCT00479986 · IKFE Institute for Clinical Research and Development, Other · Completed
Key facts
| NCT number | NCT00479986 |
|---|---|
| Title | Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease |
| Official title | Effects of Pioglitazone in Patients With Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Vascular Complications : A Placebo-Controlled Study |
| Acronym | PIOcard |
| Lead sponsor | IKFE Institute for Clinical Research and Development, Other |
| Collaborators | Takeda Industry Johannes Gutenberg University Mainz Heidelberg University |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus, Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | pioglitazone, placebo |
| Enrollment | 92 |
| Start date | Jun 1, 2005 |
| Completion | Nov 1, 2006 |
| First posted | May 30, 2007 |
| Last update posted | Apr 1, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: